Ventripoint Diagnostics Ltd. (VPTDF) 0.0300 $VPTDF
First Patients Examined with Ventripoint's Heart Analysis System in China at Shandong Provincial Hospital
Marketwired - Thu Dec 18, 6:27AM CST
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) is pleased to announce that it has installed its VMS(TM) heart analysis system at the Shandong Provincial Hospital (SPH) in Jinan, China and has examined a number of patients. The SPH does 300 cardiac ultrasound exams a day and has nine other hospitals in its group.
VPT.VN: 0.055 (unch)
Ventripoint Appoints Dr. Alan Rabinowitz to Board of Directors
Marketwired - Thu Dec 04, 7:03AM CST
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) is pleased to announce the appointment of Dr. Alan Rabinowitz to the Board of Directors.
VPT.VN: 0.055 (unch)
Ventripoint Heart Analysis System to be Exhibited at International Medical Conference in Vienna, Austria, and Grant of Stock Options
Marketwired - Wed Dec 03, 6:43AM CST
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) is pleased to announce that the Company will be exhibiting at the EuroEcho-Imaging 2014 Congress from December 3-6, 2014. More than 3,500 participants who focus on echocardiology are expected to attend EuroEcho-Imaging 2014, which is the official annual meeting of the European Association of Cardiovascular Imaging, a registered branch of the European Society of Cardiology. Held in cooperation with the Austrian Working Group of Echocardiography, the Congress takes place in Vienna, Austria, at the Reed Messe Wien GmbH Congress Center.
VPT.VN: 0.055 (unch)
Ventripoint Introduces 'Leap Frog' Diagnostic Technology in China; 230 Million Chinese Suffer From Heart Disease
ACCESSWIRE - Mon Dec 01, 8:02AM CST
Bellevue, Washington / ACCESSWIRE / December 1, 2014 / According to the World Health Association, one in five adults in China suffer from cardiovascular disease. Heart related hospital admissions in China are projected to increase by 45% between 2014 and 2030 due to high blood pressure, smoking, diabetes, pollution and an aging population.
VPT.VN: 0.055 (unch)
Ventripoint Retires All Secured Debentures
Marketwired - Wed Nov 12, 6:13AM CST
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company" (TSX VENTURE: VPT) is pleased to announce that all its secured debt has been either paid out or converted into common shares.
VPT.VN: 0.055 (unch)
Ventripoint Provides Corporate Update
Marketwired - Wed Nov 05, 7:05AM CST
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) is pleased to provide this corporate update.
VPT.VN: 0.055 (unch)
Ventripoint Announces Results of Annual Shareholders' Meeting and Grant of Stock Options and Deferred Share Units
Marketwire - Wed Sep 24, 7:53AM CDT
Ventripoint Diagnostics Ltd. (TSX VENTURE: VPT) announces that at its Annual General Meeting on September 18, 2014 the shareholders elected Dr. George Adams, Mr. Danny Dalla-Longa, Mr. Bradley Harlow and Mr. Treuman Katz as Directors of the Corporation. They further approved the Incentive Stock Option plan, amendments to the Deferred Share Unit plan (DSU plan), amendments to the By-Laws of the Corporation, and gave authority to the Board of Directors to undertake a share consolidation if it deems the consolidation in the best interests of the Corporation. BDO was appointed as auditors of the Corporation for the next year.
VPT.VN: 0.055 (unch)
German Heart Group Verifies Accuracy of Ventripoint's VMS(TM) Heart Analysis Technology for Cardiac MRI and 3D Echocardiography Imaging
Marketwire - Mon Jul 07, 10:22AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) announces that a group led by Dr. Kai Laser at the Center for Congenital Heart Defects, Bad Oeynhausen, Germany, has published the results of a clinical study that demonstrates the robust application of the VMS heart analysis technology beyond 2D ultrasound imaging in a wide range of cardiac conditions.
VPT.VN: 0.055 (unch)
Ventripoint to Exhibit at the 25th Annual Scientific Sessions of the American Society of Echocardiography
Marketwire - Fri Jun 20, 8:08AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint" (TSX VENTURE: VPT) announces that it will be exhibiting at the 25th Annual Scientific Sessions hosted by the American Society of Echocardiography (ASE) in Portland, Oregon, held June 20th through June 24th.
VPT.VN: 0.055 (unch)
Oculus Innovative Sciences, Inc. to Raise $1.35 Million in Registered Direct Offering
GlobeNewswire - Fri Feb 21, 9:00PM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) announced today that it has entered into definitive agreements with two life sciences-focused institutional investors for the sale of 450,620 units, consisting of shares of common stock, and Series A and Series B warrants, at a per unit price of $3.00 per share. The total amount sold consisted of a combination of: (1) 450,620 shares of its common stock; (2) Series A warrants to purchase up to 450,620 shares of common stock at an exercise price of $3.00 per share and a term of five years; and (3) Series B warrants to purchase up to 1,400,000 shares of common stock at an exercise price of $3.63 per share. The Series B warrants are not exercisable for six months following the closing of the IPO and have a term of 18 months. The Series B warrants have not vested and will not vest until the completion of the initial public offering (IPO) by the company's subsidiary, Ruthigen, Inc. The Series B warrants terminate on March 31, 2014, if the Ruthigen IPO has not occurred by that date.
VPT.VN: 0.055 (unch), RTGN: 3.65 (+0.10), OCLS: 1.50 (+0.01)
First Patients Examined with Ventripoint's Heart Analysis System in China at Shandong Provincial Hospital
Marketwired - Thu Dec 18, 6:27AM CST
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) is pleased to announce that it has installed its VMS(TM) heart analysis system at the Shandong Provincial Hospital (SPH) in Jinan, China and has examined a number of patients. The SPH does 300 cardiac ultrasound exams a day and has nine other hospitals in its group. VPT.VN: 0.055 (unch)
Ventripoint Appoints Dr. Alan Rabinowitz to Board of Directors
Marketwired - Thu Dec 04, 7:03AM CST
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) is pleased to announce the appointment of Dr. Alan Rabinowitz to the Board of Directors. VPT.VN: 0.055 (unch)
Ventripoint Heart Analysis System to be Exhibited at International Medical Conference in Vienna, Austria, and Grant of Stock Options
Marketwired - Wed Dec 03, 6:43AM CST
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) is pleased to announce that the Company will be exhibiting at the EuroEcho-Imaging 2014 Congress from December 3-6, 2014. More than 3,500 participants who focus on echocardiology are expected to attend EuroEcho-Imaging 2014, which is the official annual meeting of the European Association of Cardiovascular Imaging, a registered branch of the European Society of Cardiology. Held in cooperation with the Austrian Working Group of Echocardiography, the Congress takes place in Vienna, Austria, at the Reed Messe Wien GmbH Congress Center. VPT.VN: 0.055 (unch)
Ventripoint Introduces 'Leap Frog' Diagnostic Technology in China; 230 Million Chinese Suffer From Heart Disease
ACCESSWIRE - Mon Dec 01, 8:02AM CST
Bellevue, Washington / ACCESSWIRE / December 1, 2014 / According to the World Health Association, one in five adults in China suffer from cardiovascular disease. Heart related hospital admissions in China are projected to increase by 45% between 2014 and 2030 due to high blood pressure, smoking, diabetes, pollution and an aging population.
VPT.VN: 0.055 (unch)
Ventripoint Retires All Secured Debentures
Marketwired - Wed Nov 12, 6:13AM CST
Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"
(TSX VENTURE: VPT) is pleased to announce that all its secured debt has been either paid out or converted into common shares. VPT.VN: 0.055 (unch)
Ventripoint Provides Corporate Update
Marketwired - Wed Nov 05, 7:05AM CST
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) is pleased to provide this corporate update. VPT.VN: 0.055 (unch)
Ventripoint Announces Results of Annual Shareholders' Meeting and Grant of Stock Options and Deferred Share Units
Marketwire - Wed Sep 24, 7:53AM CDT
Ventripoint Diagnostics Ltd. (TSX VENTURE: VPT) announces that at its Annual General Meeting on September 18, 2014 the shareholders elected Dr. George Adams, Mr. Danny Dalla-Longa, Mr. Bradley Harlow and Mr. Treuman Katz as Directors of the Corporation. They further approved the Incentive Stock Option plan, amendments to the Deferred Share Unit plan (DSU plan), amendments to the By-Laws of the Corporation, and gave authority to the Board of Directors to undertake a share consolidation if it deems the consolidation in the best interests of the Corporation. BDO was appointed as auditors of the Corporation for the next year.
VPT.VN: 0.055 (unch)
German Heart Group Verifies Accuracy of Ventripoint's VMS(TM) Heart Analysis Technology for Cardiac MRI and 3D Echocardiography Imaging
Marketwire - Mon Jul 07, 10:22AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) announces that a group led by Dr. Kai Laser at the Center for Congenital Heart Defects, Bad Oeynhausen, Germany, has published the results of a clinical study that demonstrates the robust application of the VMS heart analysis technology beyond 2D ultrasound imaging in a wide range of cardiac conditions. VPT.VN: 0.055 (unch)
Ventripoint to Exhibit at the 25th Annual Scientific Sessions of the American Society of Echocardiography
Marketwire - Fri Jun 20, 8:08AM CDT
Ventripoint Diagnostics Ltd. ("Ventripoint"
(TSX VENTURE: VPT) announces that it will be exhibiting at the 25th Annual Scientific Sessions hosted by the American Society of Echocardiography (ASE) in Portland, Oregon, held June 20th through June 24th. VPT.VN: 0.055 (unch)
Oculus Innovative Sciences, Inc. to Raise $1.35 Million in Registered Direct Offering
GlobeNewswire - Fri Feb 21, 9:00PM CST
Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) announced today that it has entered into definitive agreements with two life sciences-focused institutional investors for the sale of 450,620 units, consisting of shares of common stock, and Series A and Series B warrants, at a per unit price of $3.00 per share. The total amount sold consisted of a combination of: (1) 450,620 shares of its common stock; (2) Series A warrants to purchase up to 450,620 shares of common stock at an exercise price of $3.00 per share and a term of five years; and (3) Series B warrants to purchase up to 1,400,000 shares of common stock at an exercise price of $3.63 per share. The Series B warrants are not exercisable for six months following the closing of the IPO and have a term of 18 months. The Series B warrants have not vested and will not vest until the completion of the initial public offering (IPO) by the company's subsidiary, Ruthigen, Inc. The Series B warrants terminate on March 31, 2014, if the Ruthigen IPO has not occurred by that date.
VPT.VN: 0.055 (unch), RTGN: 3.65 (+0.10), OCLS: 1.50 (+0.01)
